Although 13.6% of patients experienced interstitial lung disease, leading to four deaths, the US FDA granted accelerated approval for T‐DXd in adults with unresectable or metastatic HER2‐positive breast cancer who had undergone two or more prior treatments.110. This evidence concerns the gene ERBB2 and breast carcinoma.